Anzeige
Meldung des Tages: NATO-Boom und Analysten-Kursziel +100 %: Steht hier der nächste Highflyer bereit?

Precigen News

Aktie
WKN:  A2PZG1 ISIN:  US74017N1054 US-Symbol:  PGEN Branche:  Biotechnologie Land:  USA
3,815 $
-0,035 $
-0,91%
3,2301 € 26.02.26
Depot/Watchlist
Marktkapitalisierung *
1,04 Mrd. €
Streubesitz
22,79%
KGV
-2,60
Index-Zuordnung
-

Precigen News

20.01.26 - PR Newswire
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-​Line Treatment for Adults with ...
12.01.26 - PR Newswire
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-​and-Only FDA-​Approved Therapy for RRP at the 44th Annual J.P. Morgan ...
05.01.26 - PR Newswire
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
13.11.25 - PR Newswire
Precigen Reports Third Quarter 2025 Financial Results and Business Updates
Precigen Reports Third Quarter 2025 Financial Results and Business Updates PR Newswire
06.11.25 - PR Newswire
Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13
Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13 PR Newswire
13.10.25 - PR Newswire
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-​approved ...
03.09.25 - PR Newswire
Precigen Announces Up to $125 Million Non-Dilutive Financing
Precigen Announces Up to $125 Million Non-​Dilutive Financing PR Newswire
25.08.25 - PR Newswire
Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright
Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright PR Newswire
15.08.25 - PR Newswire
Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis
Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-​drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory ...
14.05.25 - PR Newswire
Precigen Reports First Quarter 2025 Financial Results and Business Updates
Precigen Reports First Quarter 2025 Financial Results and Business Updates PR Newswire
19.03.25 - PR Newswire
Precigen Reports Full Year 2024 Financial Results and Business Updates
Precigen Reports Full Year 2024 Financial Results and Business Updates PR Newswire
13.03.25 - PR Newswire
Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th
Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th PR Newswire

Newssuche

Videos

newspaper
25.02.26
So beeinflussen Margins DEIN Trading
Börsentäglich ab 18 Uhr Feierabend-​Trading Live. Teilnahme kostenlos mit diesem Link ... Mehr »